CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $195,092,582 | -18.9% | 7,089,120 | +0.0% | 0.02% | -15.0% |
| Q2 2023 | $240,491,429 | -52.8% | 7,087,870 | -50.0% | 0.02% | -13.0% |
| Q1 2023 | $509,554,372 | +61.8% | 14,162,156 | +100.5% | 0.02% | -25.8% |
| Q4 2022 | $314,885,891 | +59.7% | 7,064,974 | +0.7% | 0.03% | +47.6% |
| Q3 2022 | $197,215,000 | +4.3% | 7,015,843 | +0.0% | 0.02% | +10.5% |
| Q2 2022 | $189,074,000 | -20.8% | 7,013,144 | +0.0% | 0.02% | 0.0% |
| Q1 2022 | $238,769,000 | -11.7% | 7,010,253 | +0.2% | 0.02% | -5.0% |
| Q4 2021 | $270,464,000 | -10.8% | 6,999,580 | +24.7% | 0.02% | -16.7% |
| Q3 2021 | $303,172,000 | +2375.3% | 5,615,333 | +1433.0% | 0.02% | +2300.0% |
| Q2 2021 | $12,248,000 | +76.0% | 366,295 | +8.4% | 0.00% | 0.0% |
| Q1 2021 | $6,961,000 | – | 337,900 | +33789900.0% | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 1 | -98.6% | 0.00% | – |
| Q3 2020 | $1,000 | – | 73 | +46.0% | 0.00% | – |
| Q4 2019 | $0 | – | 50 | +150.0% | 0.00% | – |
| Q3 2019 | $0 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 761,398 | $41,108,000 | 10.12% |
| Opaleye Management Inc. | 985,000 | $53,045,000 | 9.91% |
| VR Adviser, LLC | 1,098,174 | $59,290,000 | 7.62% |
| ACUTA CAPITAL PARTNERS, LLC | 337,500 | $18,222,000 | 6.43% |
| TSP Capital Management Group, LLC | 271,429 | $14,654,000 | 5.00% |
| Ghost Tree Capital, LLC | 255,000 | $13,767,000 | 4.03% |
| COMMODORE CAPITAL LP | 248,207 | $13,401,000 | 3.53% |
| RTW INVESTMENTS, LP | 3,908,947 | $211,044,000 | 3.18% |
| Ikarian Capital, LLC | 791,600 | $42,741,000 | 3.01% |
| Redmile Group, LLC | 3,043,298 | $164,308,000 | 2.87% |